Kate Matthews, Author at UNC Children's Research Institute

Skip to main content

“Transforming Care and Inspiring Hope for all children…”

Hospital Care for Children Has Shifted from General Hospitals to Children’s Hospitals Over Last 20 Years

November 2, 2023

Children’s hospital care is now concentrated in fewer locations, and this has important implications for hospital planning and readiness, according to a new study led Michael Steiner, MD, MPH, of UNC Health. Historically, most children in the United States who needed to be hospitalized were treated at general hospitals that...

For Toddlers Allergic to Peanuts, a Tiny Bit of Protein Therapy Under the Tongue Could Be The Best Approach

October 13, 2023

A clinical study led by Edwin Kim, MD, at the UNC School of Medicine, showed how Peanut Sublingual Immunotherapy (Peanut SLIT) is safe and effective in children ranging from 1-to-4 years of age. Remission of peanut allergy was also possible after three months of stopping the treatment. A three-year clinical...

12 Months of Treatment with EPIT Superior to Placebo in Desensitizing Children to Peanuts

The study, called EPITOPE, led by senior author A. Wesley Burks, MD, CEO of UNC Health and dean of the UNC School of Medicine, and contributing author Edwin Kim, MD, MS, associate professor of pediatrics in the Division of Pediatric Allergy and Immunology at the UNC School of Medicine, shows...

Researchers Announce Findings from Landmark Clinical Trial for Pediatric Crohn’s Disease

Michael Kappelman, MD, MPH, was the lead PI on the clinical trial, which followed nearly 300 children with Crohn’s to evaluate how their conditions changed in response to anti-TNF biologic treatments alone or in combination with a second immune suppressive medication. CHAPEL HILL, N.C. – Crohn’s disease is a lifelong inflammatory...

Novel Peanut Allergy Treatment Shown to be Safe, Effective, and Lasting

A four-year clinical trial led by Edwin Kim, MD, at the UNC School of Medicine, has found that an increased dosage of a unique type of peanut allergy immunotherapy continues to show promise for children. A four-year phase 2 clinical trial demonstrated that a peanut allergy treatment called sublingual immunotherapy,...